Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10254952 | 0.92 | TACR1 (0.69) | TACR1ALDH1A1ERCC1ERCC4OPRL1 | |
| SCHEMBL2470761 | 0.88 | ALDH1A1 (0.65) | TACR1ALDH1A1ERCC1ERCC4OPRL1 | |
| SCHEMBL378738 | 0.86 | TACR1 (0.58) | TACR1ALDH1A1ERCC1ERCC4OPRM1 | |
| SCHEMBL5346968 | 0.85 | ERCC1 (0.75) | TACR1ALDH1A1ERCC1ERCC4OPRL1 | |
| SCHEMBL5704623 | 0.84 | TACR1 (0.76) | TACR1ALDH1A1ERCC1ERCC4OPRL1 | |
| SCHEMBL378422 | 0.83 | TACR1 (0.56) | TACR1OPRL1OPRM1LMNAHDAC1 | |
| SCHEMBL12194680 | 0.83 | TACR1 (0.59) | TACR1ALDH1A1ERCC1ERCC4OPRL1 | |
| SCHEMBL3816356 | 0.82 | MC4R (0.50) | TACR1TSHRSMN1; SMN2L3MBTL1SLC6A4 | |
| SCHEMBL6375805 | 0.81 | SMN1; SMN2 (0.57) | TACR1ALDH1A1ERCC1ERCC4OPRM1 | |
| SCHEMBL21077981 | 0.81 | SMN1; SMN2 (0.51) | TACR1OPRL1OPRM1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409457-A1 | METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE | Sanofi-Aventis (FR) | 2004-04-21 | — | — | EP | claimed |
| WO-2003008381-A1 | METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | claimed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2411383-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2324015-A2 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-aventis (FR) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010109150-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1501467-A4 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
| EP-1501467-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040110793-A1 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| EP-1409457-A1 | METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE | Sanofi-Aventis (FR) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003088908-A2 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003008381-A1 | METHOD FOR PREPARING 4-METHYLAMINO-4-PHENYLPIPERIDINE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | TACR1 3354/4885ALDH1A1 3941/4885ERCC1 2042/4885 |
| US-20040110793-A1 | Heterocyclo inhibitors of potassium channel function | KCNH2, KCNN1, KCNJ2 | TACR1 3807/4885ALDH1A1 3045/4885ERCC1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.